Janux Therapeutics (JANX) FCF Margin (2021 - 2026)

Janux Therapeutics (JANX) posted quarterly FCF Margin of 337.8% for Q1 2026, down 160.87% quarter-over-quarter from 129.49% in Q3 2025.

Janux Therapeutics (JANX) FCF Margin (2021 - 2026) Analysis & Trends

Janux Therapeutics (JANX) has reported FCF Margin for 6 consecutive years, with 337.8% the latest figure, recorded in Q1 2026.

In Q1 2026, FCF Margin changed N/A year-over-year to 337.8%; the TTM figure through Mar 2026 stood at 565.33% (down 7168.0% YoY), while the FY2025 annual figure was 819.59%, down 40224.0% from the prior year.
FCF Margin slipped to 337.8% in Q1 2026 per JANX's latest filing, from 129.49% in the prior quarter.
Across five years, FCF Margin topped out at 113.7% in Q2 2024 and bottomed at 1495.93% in Q2 2023.
Historically, FCF Margin has averaged 577.74% across 5 years, with a median of 451.25% in 2024.
Annual changes were most pronounced in 2022 — FCF Margin plunged 221398 bps — and 2024, when it jumped 138223 bps.
Janux Therapeutics' FCF Margin stood at 429.74% in 2022, then gained by 2 bps to 423.24% in 2023, then fell by 7 bps to 451.25% in 2024, then soared by 71 bps to 129.49% in 2025, then sank by 161 bps to 337.8% in 2026.
Business Quant data shows JANX's FCF Margin at 337.8% in Q1 2026, 129.49% in Q3 2025, and 451.25% in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	13.35%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	25.68%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-77,594.17%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	70.82%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	22.62%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-22.35%
10	Janux Therapeutics	984.58 Mn	984.58 Mn	-	129.98%

Download Data